Volume 15, Issue 2 (11-2025)
Clin Exc 2025, 15(2): 81-91 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Torabi M, Azizi Shoul S, Soltaninejad S. The Prevalence of Hepatopancreas Injury and Its Clinical Outcome in Patients with Coronavirus Disease 2019 (COVID-19). Clin Exc 2025; 15 (2) :81-91
URL: http://ce.mazums.ac.ir/article-1-891-en.html
URL: http://ce.mazums.ac.ir/article-1-891-en.html
Afzalipour Hospital Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Abstract: (7 Views)
Background and purpose: This study aimed to examine the prevalence of hepatopancreas injury and its associated clinical outcomes in patients with COVID-19.
Materials and Methods: This cross-sectional study included patients with COVID-19 admitted to the hospital within six months. Liver injury was defined as an aspartate aminotransferase (AST) or an alanine aminotransferase (ALT) level exceeding 37 or 50 units per liter (U/L), respectively. Pancreatic injury was defined as an amylase exceeding 115 U/L. The data were analyzed using GraphPad Prism.
Results: A total of 71 patients were included. The prevalence of hepatopancreas injury in patients with COVID-19 was reported to be 61.97%. The mortality rate was 32.39%. The most prevalent chronic disease was diabetes (32.39%). A significant correlation was observed between hepatopancreas injury and gender, as well as liver enzymes (AST, ALT, and lactate dehydrogenase [LDH]) (P-value < 0.05). Nevertheless, no significant correlation was observed between remdesivir consumption and liver enzyme levels, amylase levels, or mortality.
Conclusion: More than 60% of patients with COVID-19, especially men with diabetes, develop hepatopancreatic injury. The possibility of this injury is suggested by increased liver enzymes (AST, ALT, LDH), but their predictive value for mortality was not confirmed in this study.
Materials and Methods: This cross-sectional study included patients with COVID-19 admitted to the hospital within six months. Liver injury was defined as an aspartate aminotransferase (AST) or an alanine aminotransferase (ALT) level exceeding 37 or 50 units per liter (U/L), respectively. Pancreatic injury was defined as an amylase exceeding 115 U/L. The data were analyzed using GraphPad Prism.
Results: A total of 71 patients were included. The prevalence of hepatopancreas injury in patients with COVID-19 was reported to be 61.97%. The mortality rate was 32.39%. The most prevalent chronic disease was diabetes (32.39%). A significant correlation was observed between hepatopancreas injury and gender, as well as liver enzymes (AST, ALT, and lactate dehydrogenase [LDH]) (P-value < 0.05). Nevertheless, no significant correlation was observed between remdesivir consumption and liver enzyme levels, amylase levels, or mortality.
Conclusion: More than 60% of patients with COVID-19, especially men with diabetes, develop hepatopancreatic injury. The possibility of this injury is suggested by increased liver enzymes (AST, ALT, LDH), but their predictive value for mortality was not confirmed in this study.
Keywords: Coronavirus disease 2019 (COVID-19), Hepatopancreas injury, Outcome, Mortality, Remdesivir.
Type of Study: Research(Original) |
Subject:
طب اورژانس
Received: 2025/02/18 | Accepted: 2025/10/26 | Published: 2025/10/26
Received: 2025/02/18 | Accepted: 2025/10/26 | Published: 2025/10/26
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
